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Abstract
Purpose Tumour-infiltrating lymphocytes (TILs) have been shown to be prognostic for disease-free survival and predictive 
for the benefit of chemotherapy in patients with early breast cancer, but have not been studied for endocrine therapy.
Experimental design The number of CD8-positive TILs was assessed in a subcohort of 236 patients in the Intergroup 
Exemestane Study. AQ After 2–3 years of adjuvant tamoxifen, AQpatients were randomized between the schemes of con-
tinuation for 5 years on tamoxifen and switching to exemestane. The numbers of CD8-positive TILs were analysed for cor-
relations with disease-free survival (DFS) and overall survival (OS). A similar analysis was performed on 2596 patients in 
the TEAM trial who were randomized between the sequential scheme and the exemestane monotherapy.
Results In the first cohort, patients with low (below median) numbers of CD8-positive TILs had a univariate hazard ratio 
(HR) for DFS of 0.27 (95% CI 0.13–0.55) in favour of treatment with exemestane, whereas this benefit was not observed in 
patients with high numbers of CD8-positive TILs (HR 1.34, 95% CI 0.71–2.50, HR for interaction 5.02, p = 0.001). In the 
second cohort, patients with low numbers of CD8-positive TILs showed a benefit of exemestane treatment on recurrence-
free survival (RFS HR 0.67, 95% CI 0.45–0.99), and not with above-median numbers of CD8-positive TILs (HR 0.86, 95% 
CI 0.59–1.26, HR for interaction 1.29, p = 0.36).
Conclusions This study is the first to propose the number of CD8-positive TILs as potential predictive markers for endo-
crine therapy, with the low presence of CD8-positive TILs associated to benefit for exemestane-inclusive therapy. However, 
treatment-by-marker interactions were only significant in one cohort, indicating the need for further validation.
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Introduction
Approximately 75% of all breast cancer patients have estro-
gen receptor (ER)-positive tumours, and are candidates 
for adjuvant endocrine treatment with either an aromatase 
inhibitor (AI) or the selective estrogen receptor modulator 
(SERM), tamoxifen. AQAmong other studies, the phase 
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III Intergroup Exemestane Study (IES), which randomized 
4724 postmenopausal patients with early-stage breast cancer 
after 2–3 years of tamoxifen therapy between the schemes 
of continuing on tamoxifen and switching to exemestane to 
complete 5 years of endocrine therapy, showed a signifi-
cantly improved disease-free survival (DFS) in favour of 
a switch to exemestane after 2–3 years of tamoxifen, com-
pared to 5 years of tamoxifen monotherapy [1–4]. A second 
study, the tamoxifen, exemestane adjuvant multinational 
(TEAM) phase 3 trial, was performed to assess the benefit 
of 5-year exemestane monotherapy over the switch scheme, 
and showed no statistical differences in survival between 
both groups [5].
Classic prognostic factors like TNM-stage, tumour 
grade and expressional status of hormone receptors or the 
human epidermal growth factor receptor 2 (HER2) do not 
predict which adjuvant endocrine treatment is the best one 
for which patient [5]. One of the factors that could act as a 
new prognostic or predictive biomarker may be derived from 
the immune system. The importance of the local immune 
system, in particular, the role of tumour-infiltrating lympho-
cytes (TILs) on the outcome of (neo)adjuvant treatment of 
breast cancer has recently been validated [6–13]. Cytotoxic 
(CD8-positive) T-cells appear to play a major role in this 
phenomenon [7, 9]. Most of the studies reported a clini-
cal benefit for tumours with a higher infiltration of TILs, 
although this effect seems to be isolated to rapidly prolif-
erating, ER-negative tumours [7–12]. Especially in triple-
negative tumours, TILs are a promising biomarker for the 
success of (neo)adjuvant chemotherapy [6, 13]. However, no 
data are available which assess the predictive value of TILs 
for endocrine treatment.
The aim of the current study was to determine the prog-
nostic value of CD8-positive TILs in ER-positive breast 
cancer, and predictive value of CD8-positive TILs on the 
outcome of endocrine therapy with either tamoxifen or 
exemestane in two independent cohorts. For this, we evalu-
ated the number of CD8-positive TILs in the Dutch subsets 
of the IES and TEAM trials, and used this for a stratified 
survival analysis for tumour recurrence and survival time of 
patients treated with either exemestane or tamoxifen.
Materials and methods
Patients and tumour tissues
IES trial
In the IES trial, 4724 patients, who were treated with sur-
gery for early breast cancer and who were disease free after 
2–3 years of adjuvant treatment with tamoxifen, were ran-
domized based on either continuing with tamoxifen for up 
to 5 years, or switching to exemestane to complete 5 years 
of therapy, between 1998 and 2003. The details on inclu-
sion and exclusion criteria were described before [3]. For 
the Dutch fraction of this cohort (n = 236), formalin-fixed 
paraffin-embedded (FFPE) tumour tissue was collected and 
was separately converted into a tissue microarray (TMA). 
This TMA was created as described earlier [14]. In brief, 
two 0.6-mm-core needle punches were obtained from the 
FFPE tumour blocks, and transplanted into an empty recipi-
ent block. Follow-up for disease-free survival (DFS, defined 
as any local, regional or distant recurrence, new contralateral 
breast cancer or death due to any cause) and overall survival 
(OS) started at randomization after 2–3 years of tamoxifen 
treatment. For this analysis, follow-up data were used which 
were described earlier [4].
TEAM trial
The TEAM trial consists of 9779 patients who were rand-
omized for adjuvant treatment between the switch schemes 
(2.5 years tamoxifen followed by 2.5 years of exemestane) 
and 5 years of exemestane, between 2001 and 2006. The 
details of this trial were described earlier [5, 15]. FFPE 
tumour tissue was collected for the Dutch part of this trial 
(n = 2596), and embedded in triplicate on a TMA with 
0.6-mm punches. Since both randomization arms were 
similar after the moment of switch, we censored the follow-
up at 2.75 years (which was the middle between 2.5 and 
3 years, the timeframe for patients in the switch group to 
switch to exemestane) in order to solely compare the dif-
ferential effects of exemestane and tamoxifen. Beyond 
these 2.75 years, both treatment groups were treated with 
exemestane, which could interfere with the marker-by-treat-
ment interaction. Due to the censoring at 2.75 years, only 
the recurrence-free survival (RFS), defined as any breast 
cancer recurrence or death due to breast cancer if no recur-
rence was reported before death, was used as a parameter 
of clinical outcome in this study since this censoring did 
not allow sufficient time to have an effect on mortality out-
comes. All samples of both cohorts were handled in a coded 
fashion, according to national ethical guidelines (‘‘Code for 
Proper Secondary Use of Human Tissue’’, Dutch Federation 
of Medical Scientific Societies).
Immunohistochemical staining
The procedures for the used immunohistochemical staining 
have been described before by our group in multiple dif-
ferent cohorts [8, 16]. In short, 4 µm sections from FFPE 
TMA blocks were deparaffinised in xylene and subsequently 
hydrated using graded alcohol washes, before endogenous 
peroxidase was blocked using hydrogen peroxide. Antigen 
retrieval was performed at 95 degrees Celsius for 10 min 
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in a pH low target retrieval solution (DAKO, Glostrup, 
Denmark). The sections were incubated overnight at room 
temperature with primary antibodies against CD8 (clone 
144B, Abcam, Cambridge, UK) at a predetermined optimal 
dilution using proper positive and negative controls. After 
washing, the sections were incubated with specific horserad-
ish peroxidase-labelld Envision + System-HRP (DAKO) for 
30 min, before they were stained using 3,3′-diaminobenzi-
dine (DAB) solution (DAKO). Subsequently, the slides were 
counterstained for 30 s in haematoxylin, dehydrated using 
inverse-graded alcohol washes and xylene, and mounted 
in Pertex before they were dried and stored until further 
analysis.
Evaluation of immunohistochemical staining
Slides were scanned using an automated scanner (Philips, 
Eindhoven, Netherlands), and obtained digital images 
were stored on an internal server until later analysis. Each 
punch,at least 30% of the total area of which had tumour 
cells, was individually assessed for the number of CD8-
positive cells in the punch by a trained investigator, after 
completing training by a pathologist. Results from duplicate 
(IES) or triplicate (TEAM) punches were then combined in 
order to determine the average score per patient. The median 
cohort value was used as a cut-off for dichotomous analysis 
for infiltrating cells. Since the evaluation in the TEAM trial 
was intended as a proof of principle and not as a formal vali-
dation, the median value of this TEAM cohort was assessed 
separately, and used as the cut-off for this cohort. One-third 
of all measurements were scored by an independent second 
observer, and in case of disagreement about the dichotomous 
classification, the punch was reviewed and discussed by both 
observers until agreement was reached.
Statistical analysis
The study was a non-planned, retrospective, explorative 
project, for which all available cases were used without a 
predefined sample size calculation to detect a specific effect 
size or reach a certain level of power. ANOVA and post hoc 
Bonferroni tests (corrected for multiple testing) were used to 
assess the mean number of CD8-positive TILs per subgroup. 
The kappa measurement for overall inter-observer agree-
ment was used to assess the inter-observer variation for the 
dichotomized scores in one-third of all cases. Cox regres-
sion modelling was used to assess DFS and OS in the IES 
cohort, and RFS in the TEAM cohort, correct for possible 
confounders, and perform a treatment-by-marker interaction 
test. Missing data were included in models when they were 
missing in more than 10% of cases. Kaplan–Meier curves 
and the corresponding Log-rank tests were used to visual-
ize these survival effects. Reverse Kaplan–Meier was used 
to determine the median follow-up duration. Furthermore, 
a post hoc analysis was performed at which every threshold 
was tested to determine which cut-off point would lead to the 
most discriminate HR for interaction. All statistical analyses 
were performed using SPSS version 23 (IBM).
Results
The Dutch IES cohort consisted of 236 postmenopausal 
patients with early breast cancer (Fig. 1a). After creating 
the TMA, cores containing sufficient tumour tissue (> 30%) 
were available from 190 patients. Patient and tumour charac-
teristics are shown in Table 1. The median age was 64 years 
(range 30–96 years). The median follow-up was 10.1 years 
(range 0.49–11.34 years). No significant differences in the 
number of CD8-positive TILs were observed between clin-
icopathological subgroups (Table 1). The median number 
of CD8-positive cells per punch was 4, which is equivalent 
to 14 cells/mm2.
In the TEAM cohort, tumour tissues of 2596 patients 
were stained and scored for the presence of CD8-positive 
TILs. Sufficient cores (a minimum of 2 cores, containing at 
least 30% tumour tissue) were available for 2345 patients 
(90%). Punches showing artefacts or lack of tumour cells 
in the punches were excluded from analysis. The median 
follow-up, as determined by reverse Kaplan–Meier analy-
sis, was 2.75 years (range 0–2.75). The distribution of clin-
icopathological subtypes was comparable to the IES cohort 
(Table 1). A number of significant differences in the num-
ber of CD8-positive TILs was observed between subgroups; 
patients above the age of 70 had a lower number of CD8-
positive TILs compared to patients aged either 50–59 or 
60–69 (Table 1). Furthermore, there was a significant asso-
ciation with tumour grade (more CD8-positive TILs with 
higher grade) and with HER2 expression (more CD8-posi-
tive TILs in HER2-positive tumours). The median number 
of CD8-positive TILs in this cohort was 6 per punch, which 
is equivalent to 20 cells/mm2. The overall kappa measure 
for accordance in both cohorts was 0.65, after which each 
discordant case was discussed until consensus was reached.
In the IES cohort, there was no prognostic value in the 
number of CD8-positive TILs for the full population for 
either DFS or OS (Fig. 2a, b). One of the aims of this study 
was to determine the predictive value of the number of CD8-
positive TILs. Therefore, we stratified the survival analysis 
on the number of CD8-positive TILs (Table 2). It was shown 
that patients having a below-median number of CD8-posi-
tive TILs had a significantly better DFS when treated with 
exemestane after earlier tamoxifen compared to tamoxifen 
monotherapy (Fig. 3a). In 97 patients with a below-median 
number of CD8-positive TILs, 10 out of 45 patients on 
exemestane experienced a DFS-event, whereas 31 out of 52 
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patients allocated to tamoxifen encountered a DFS-event. 
Univariate cox regression showed a hazard ratio (HR) for 
DFS of 0.27 (95% CI 0.13–0.55, p < 0.001) in favour of 
exemestane treatment in these patients, with an adjusted HR 
(corrected for age, histological subtype, tumour size, lymph 
node status, tumour grade and PgR status) of 0.35 (95% CI 
0.16–0.78) (Table 2). In contrast, in patients with above-
median numbers of CD8-positive TILs, there was no signifi-
cant difference in benefits of either therapy (events: 23 out of 
49 on exemestane, 17 out of 44 patients on tamoxifen) with 
a HR of 1.34 (95% CI 0.71–2.50, p = 0.36) and an adjusted 
HR of 1.21 (95% CI 0.58–2.51, p = 0.97) (Fig. 2b). The HR 
for treatment-by-marker interaction between these groups 
was 5.02 (95% CI 1.93–13.02 p = 0.001), showing that 
the difference in treatment effects between the two marker 
groups was statistically significant. Although underpowered 
due to the small cohort size and relatively low numbers of 
events, the adjusted HR for interaction was 3.34 (95% CI 
1.17–9.56, p = 0.02) when corrected for age, histological 
subtype, tumour size, lymph node status, tumour grade and 
PgR status.
Similar results were shown for overall survival, where 
a statistically significant benefit was shown for patients 
with a below-median number of CD8-positive TILs when 
treated with the switch scheme. In 97 patients with a below-
median number of CD8-positive TILs, 9 out of 45 patients 
on exemestane had died at the end of follow-up, whereas 23 
out of 52 patients allocated to tamoxifen were not alive at 
the end of follow-up (HR 0.38, 95% CI 0.17–0.82, p = 0.014; 
adjusted HR 0.48, 95% CI 0.19–1.18, p = 0.15). In patients 
with an above-median number of CD8-positive TILs, there 
was no difference (HR 1.13, 95% CI 0.56–2.30, p = 0.73; 
adjusted HR 1.07, 95% CI 0.46–2.49, p = 0.78), with 17 out 
of 49 patients having died on exemestane and 14 out of 44 
patients having died on tamoxifen (Fig. 3c, d). Also for over-
all survival, a significant treatment-by-marker interaction 
was observed (HR for interaction 3.01, 95% CI 1.05–8.58, 
p = 0.04). The (underpowered) adjusted HR for interaction 
was 2.43 (95% CI 0.75–7.88, p = 0.14).
In a post hoc analysis, it was established that the median 
value of 4 cells per punch (14 cells/mm2) was close to the 
optimal threshold level of 3 cells per punch (11 cells/mm2), 
which would have resulted in the highest predictive effect 
of CD8-positive TILs (Supplemental Fig. 1) in the Dutch 
IES cohort.
In order to further explore the observed interaction 
between the outcome of endocrine therapy and the number 
of CD8-positive TILs, a similar analysis was performed in 
the Dutch TEAM cohort. Only the first 2.75 years of fol-
low-up were considered for survival analysis, since after 
this timepoint, patients in both groups received exemestane 
which would diminish any biological interaction.
It was established that also in this cohort, the number of 
CD8-positive TILs had no prognostic effect on recurrence 
either censored at 2.75 years (HR 0.91, 95% CI 0.69–1.19, 
p = 0.47) or at full length of follow-up (HR 1.0, 95% CI 
0.85–1.18 p = 0.97). With regard to the predictive value, 
it was shown that patients with a below-median number 
of CD8-positive TILs, had a HR for tumour recurrence of 
0.67 (95% CI 0.45–0.99, p = 0.048) in favour of exemes-
tane treatment, whereas patients with above-median num-
bers of CD8-positive TILs had a HR of 0·86 (95% CI 
0.59–1.26, p = 0.44), which was similar to the findings of 
the first cohort (Fig. 4a, b). The adjusted HRs were not 
IES trial (n=4726)
Excluded (n=3470)
No tissue collected
Tissue available 
(n=1256)
Data and tissue available
on TMA for Dutch 
patients (n=236)
Excluded (n=1020)
Non-Dutch patients
Stained samples for 
analysis (n=190)
Excluded (n=46)
Missing punches 
No tumour tissue
TEAM trial (n=9779)
Excluded (n=7183)
No tissue collected
Tissue available 
(n=2596)
Data and tissue available
on TMA for Dutch 
patients (n=2596)
Stained samples for 
analysis (n=2345)
Excluded (n=251)
Missing punches 
No tumour tissue
CD8 stainingCD8 staining
. .
.
.. ..
Fig. 1  Flowcharts of the used cohorts for this study. The Dutch part of the Intergroup Exemestane Study (IES) (a) and the Dutch part of the 
international TEAM trial (b) were assessed for the number of CD8-positive TILs and its predictive value for endocrine therapy
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significant in either the CD8-low or CD8-high group (low 
numbers of CD8-positive TILs: 0.71, 95% CI 0.47–1.07, 
p = 0.10; high numbers of CD8-positive TILs: 0.82, 95% 
CI 0.56–1.21, p = 0.32). The treatment-by-marker interac-
tion was not significant in this cohort (HR for interaction 
1.29, 95% CI 0.75–2.22, p = 0.36, adjusted HR for interac-
tion 1.20, 95% CI 0.68–2.11, p = 0.52).
Table 1  The clinicopathological 
features of both cohorts, 
including the mean number of 
CD8-positive TILs per punch 
for each subgroup
Statistical testing was performed using X2, ANOVA and post hoc Bonferroni testing. Each significant asso-
ciation is indicated by a separate character (a, b, c). No significant differences were observed between sub-
groups of both cohorts
*Post-hoc Bonferroni test < 0.05 (each association is indicated by a separate character)
IES cohort patients CD8+ TILs TEAM cohort patients CD8+ TILs
n % Mean (n) n % Mean (n)
Age
 < 50 3 1.6 24 52 2.2 9
 50–59 60 31.6 13 713 30.4 17*a
 60–69 60 31.6 15 810 34.5 16*b
 > 70 67 35.3 13 770 32.8 12*a,b
Histological subtype
 Ductal 132 69.5 13 1758 78.7 15
 Lobular 36 18.9 15 368 16.5 14
 Other 22 11.6 18 109 4.9 13
 Missing – – – 110 – –
Bloom & Richardson grade
 Grade 1 14 13.6 11 350 16.0 10*a,b
 Grade 2 50 48.5 11 1022 46.6 15*b,c
 Grade 3 38 36.9 12 820 37.4 18*a,c
 Grade 4 1 1.0 43 2 0.1 37
 Missing 87 – – 151 – –
Tumor size
 0–3 cm 134 73.2 15 1833 78.5 15
 3–5 cm 38 20.8 11 399 17.1 14
 >5 cm 11 6.0 9 103 4.4 16
 Missing 7 – – 10 – –
Nodal status
 No 56 30.3 19 714 31.3 17
 1–3 N+ 90 48.6 11 1172 51.4 14
 NI N+ 39 21.1 9 394 17.3 15
 Missing 5 – – 65 – –
PgR expression
 No 36 21.6 19 509 23.0 17
 Yes 131 78.4 13 1702 77.0 15
 Missing 23 – – 134 – –
HER2 expression
 No – – – 1991 88.4 15*
 Yes – – – 261 11.6 19*
 Missing 190 – – 93 – –
Type of surgery
 Wide local excision 83 46.1 16 1039 44.3 17
 Mastectomy 97 53.9 12 1305 55.7 14
Missing 10 – – 1 – –
Allocated treatment
 Exemestane 94 49.5 17 1187 50.6 16
 Tamoxif en 96 50.5 11 1158 49.4 15
 Breast Cancer Research and Treatment
1 3
Discussion
This study is the first to investigate CD8-positive TILs as 
a predictive biomarker for the type of adjuvant endocrine 
therapy in postmenopausal patients with early breast cancer. 
In the first IES cohort, patients with a low number of CD8-
positive TILs had significantly greater treatment benefit from 
aromatase inhibitors (AIs) than from tamoxifen, whereas 
the type of therapy did not make any difference in patients 
with high numbers of CD8-positive TILs. The treatment-by-
marker interaction, comparing the clinical benefit in both 
subgroups, was significant despite the low number of events 
in this analysis, suggesting a predictive capacity of CD8-
positive TILs for endocrine therapy. In the second TEAM 
cohort, it was similarly suggested that patients with low lev-
els of CD8-positive TILs had greater treatment benefit from 
exemestane. However, the treatment-by-marker interaction 
in this cohort was not significant, indicating that the benefit 
of exemestane in the CD8-low group was not significantly 
different from the benefit in the CD8-high subgroup.
The difference in significance between both cohorts can 
be explained by several factors. First, the IES cohort was 
smaller, and thereby underpowered for definite conclusions 
since it is more sensitive for random variation and artefac-
tual findings. Secondly, all patients in the IES cohort were 
pre-treated with 2–3 years of tamoxifen, whereas the TEAM 
patients were treatment-naïve at the time of randomization. 
This pre-treatment, and the subsequent carry-over effect 
known from tamoxifen, could have influenced the differ-
ences between both cohorts. Finally, in the TEAM cohort, 
the follow-up was censored to 2.75 years, which limited 
the number of events and therefore hampered the required 
power for survival and interaction analysis. Furthermore, 
late recurrences are a major issue in ER-positive disease, 
which limits the possibility to draw conclusions on these 
short follow-up data. In contrast, the analysis in the IES 
cohort started at 2–3 years after diagnosis, and was contin-
ued up to almost 12 years post diagnosis. This difference 
in follow-up periods could have influenced the comparison 
between both cohorts as well.
At baseline, we showed in the TEAM cohort that there 
are statistically significant differences in the numbers of 
CD8-positive TILs between some subgroups. However, the 
absolute differences are small, and will most likely have no 
clinical relevance.
Earlier studies showed that TILs have no prognostic 
value in ER-positive disease [9, 12]. We confirmed these 
findings in both of our cohorts, showing that the number 
of CD8-positive TILs on itself had no prognostic value in 
both ER-positive cohorts. Interestingly, the suggestion that 
treatment with exemestane could be particularly beneficial 
for patients with a low number of infiltrating CD8-positive 
T-cells, as suggested by some of our results, has never been 
shown before in a trial-based translational study.
The mechanism behind the possible greater beneficial 
effect of aromatase inhibitors in case of low levels of CD8 
positive cells is unknown yet. Various hypothesis can be 
made. One earlier study has suggested that the effect of AIs 
is dependent on immune suppression rather than activation 
[17]. In this study, they obtained 81 paired samples before 
and after 2 weeks of neoadjuvant anastrozole, and performed 
a multigene expression profile of these samples. In total, 
1327 genes were differentially expressed. It was observed 
that a higher baseline expression of proinflammatory genes 
correlated to a poor therapeutical effect of anastrozole, and 
lymphocytic infiltration correlated to a poorer therapeutical 
response to AIs, which was similarly observed by others 
[17, 18]. Gao et al. validated these findings by showing that 
a high expression of genes associated with immune reaction 
predicted a poor response to endocrine therapy [19].
Aromatase inhibitors might also play a role in modulat-
ing the local immune response. For example, according to 
Fig. 2  The general prognostic effect of CD8-positive TILs on either 
DFS (left) or OS (right) for all (ER-positive) patients using Kaplan–
Meier survival analysis. The number of CD8-positive TILs was strati-
fied as low (below median) and high (above median) relative to the 
median value. Event rates are provided in the graph, and numbers at 
risk below the graph. P-values were determined using a Log-rank test
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the study of Generali et al., aromatase inhibitors are capa-
ble of lowering the number of tumour-infiltrating regula-
tory T-cells, and thereby may improve treatment outcome 
[20]. Similar results were shown by Chan et al., who stud-
ied the ratio of cytotoxic T-cells and regulatory T-cells dur-
ing neoadjuvant endocrine treatment and observed a sig-
nificant increase of this ratio in responders, as opposed to 
non-responders [21]. Moreover, aromatase inhibitors have 
been shown to enhance cytokine excretion and the sever-
ity of experimental polyarthritis in murine models, indicat-
ing an activation of the immune system [22]. Furthermore, 
auto-immune conditions have been suggested as a contribut-
ing factor to often-reported arthralgia [23]. Based on these 
abovementioned findings, it could be hypothesized that 
aromatase inhibitors exert part of their function by acti-
vating both the systemic and the local immune responses. 
Therefore, patients with a weaker local immune response at 
baseline will benefit more from AIs, since the immunomod-
ulation will result in greater effect in those patients com-
pared with patients who already have a strong local immune 
response. However, these studies were performed in the neo-
adjuvant setting with the primary tumour still in situ, so they 
Fig. 3  The predictive value of 
CD8-positive TILs on endocrine 
therapy in the IES cohort using 
Kaplan–Meier survival analysis. 
Patients with below-median 
(low) numbers of CD8-positive 
TILs are shown in the left-
side graphs (DFS above OS), 
patients with above-median 
(high) numbers of CD8-positive 
TILs in the right-side graphs. 
Event rates are provided in the 
graph, numbers at risk below 
the graph. p-values were deter-
mined using a Log-rank test
Fig. 4  The predictive value of CD8-positive TILs on endocrine 
therapy in the TEAM cohort using Kaplan–Meier survival analysis, 
stratified based on the median number of CD8-positive TILs. Patients 
with below-median (low) numbers of CD8-positive TILs are shown 
on the left, and patients with above-median (high) numbers of TILs 
on the right. Inserts show a more detailed graph with a range of 
80–100% survival. Event rates are provided in the graph, numbers at 
risk below the graph. p-values were determined using a Log-rank test
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are not directly comparable to our adjuvant trial where the 
primary tumour was removed before endocrine treatment.
Another theory for explaining the possible differen-
tial effects of AIs and tamoxifen between TIL-rich and 
TIL-poor tumours is that the number of infiltrating CD8-
positive TILs is a proxy variable for another tumour char-
acteristic, which might be the mutational load. Earlier, it 
was established that the mutational load in the tumour, 
and therefore the number of neo-epitopes, is associated 
with the local immune response [24]. Furthermore, it has 
been shown that more aggressive Luminal B-type tumours, 
which are generally considered less responsive to endo-
crine therapy, have higher mutational load compared with 
the more responsive Luminal A subtype [25, 26]. Hypo-
thetically, tumours with a lower mutational load might be 
more dependent on ER-pathway signalling, since they are 
less likely to acquire activating mutations in other onco-
genes, whereas tumours with a higher mutational load 
have activated other growth-stimulating pathways and 
are therefore less dependent on ER-signalling for their 
survival. These results suggest that AIs would be the 
most optimal strategy for strongly ER-dependent (lower 
mutational load) tumours, whereas tamoxifen and AIs are 
equally good for less ER-dependent tumours.
A weakness of the current study is the fact that the Dutch 
fraction of IES-trial patients is only a small fraction of the 
full IES population (5%). Although randomization was strat-
ified on individual centres, and therefore our cohort is still 
balanced between the treatment arms, it might still be that 
our cohort is biased compared to the full trial population. 
Furthermore, we evaluated the number of CD8-positive TILs 
on a TMA using immunohistochemistry, while the evalu-
ation of TILs in the regular clinical setting is usually per-
formed on full H&E stained slides. Therefore, our results 
need to be validated using this approach before clinical 
implementation might become feasible.
In summary, the current study provides the first sugges-
tion that the number of CD8-positive TILs could be used as 
a predictive marker in the endocrine treatment of breast can-
cer. Upon further validation in a trial with a similar design 
as IES in which tamoxifen monotherapy is compared to an 
AI-containing regime, patients with low numbers of CD8-
positive TILs could derive more benefit from AIs than that 
from tamoxifen, whereas patients with a strong infiltration 
of CD8-positive TILs derive a similar outcome on both 
treatment strategies. Future studies will be directed towards 
validation of these findings for other aromatase inhibitors, 
to show whether the results observed for exemestane can 
be extrapolated to letrozole or anastrozole as well. Our 
findings might contribute to a more optimized treatment 
of hormone-receptor-positive breast cancer using the local 
immune system as a predictive biomarker for adjuvant endo-
crine therapy.
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